A Novel Small-Molecule Inhibitor of Transforming Growth Factor β Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection
The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Malignant mesothelioma is an aggressive and lethal pleural cancer that overexpresses transforming growth factor beta (TGFbeta). We investigated the efficacy of a novel small-molecule TGFbeta type I receptor (ALK5) kinase inhibitor, SM16, in the AB12 syngeneic model of malignant mesothelioma. SM16 inhibited TGFbeta signaling seen as decreased phosphorylated Smad2/3 levels in cultured AB12 cells (IC(50), approximately 200 nmol/L). SM16 penetrated tumor cells in vivo, suppressing tumor phosphorylated Smad2/3 levels for at least 3 h following treatment of tumor-bearing mice with a single i.p. bolus of 20 mg/kg SM16. The growth of established AB12 tumors was significantly inhibited by 5 mg/kg/d SM16 (P < 0.001) delivered via s.c. miniosmotic pumps over 28 days. The efficacy of SM16 was a result of a CD8+ antitumor response because (a) the antitumor effects were markedly diminished in severe combined immunodeficient mice and (b) CD8+ T cells isolated from spleens of mice treated with SM16 showed strong antitumor cytolytic effects whereas CD8+ T cells isolated from spleens of tumor-bearing mice treated with control vehicle showed minimal activity. Treatment of mice bearing large tumors with 5 mg/kg/d SM16 after debulking surgery reduced the extent of tumor recurrence from 80% to <20% (P < 0.05). SM16 was also highly effective in blocking and regressing tumors when given p.o. at doses of 0.45 or 0.65 g/kg in mouse chow. Thus, SM16 shows potent activity against established AB12 malignant mesothelioma tumors using an immune-mediated mechanism and can significantly prevent tumor recurrence after resection of bulky AB12 malignant mesothelioma tumors. These data suggest that ALK5 inhibitors, such as SM16, offer significant potential for the treatment of malignant mesothelioma and possibly other cancers.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, TGF-β pathway blocking can lead to a substantial inhibition of the in vivo growth of mesothelioma [39].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [39]
Citations
Cites
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355
Gorelik, L., & Flavell, R. A. (2001) · Nature Medicine · doi:10.1038/nm1001-1118 · Cited by 770
Role of Transforming Growth Factor Beta in Human Cancer
Elliott, R. L., & Blobe, G. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.047 · Cited by 709
TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis
Oft, M., Heider, K.-H., & Beug, H. (1998) · Current Biology · doi:10.1016/s0960-9822(07)00533-7 · Cited by 623
Development of TGF-β signalling inhibitors for cancer therapy
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1580 · Cited by 549
Liau, L. M., Prins, R. M., Kiertscher, S. M., Odesa, S. K., Kremen, T. J., Giovannone, A. J., Lin, J.-W., Chute, D. J., Mischel, P. S., Cloughesy, T. F., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0464 · Cited by 543
Siegel, P. M., Shu, W., Cardiff, R. D., Muller, W. J., & Massagué, J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932636100 · Cited by 429
Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases
Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S., Gotwals, P. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215234 · Cited by 415
Uhl, M., Aulwurm, S., Wischhusen, J., Weiler, M., Ma, J. Y., Almirez, R., Mangadu, R., Liu, Y.-W., Platten, M., Herrlinger, U., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1013 · Cited by 414
Research works printed but not linked: 1
- Singh J, Ling LE, Sawyer JS, Lee WC, Zhang F, Yingling JM. Transforming the TFGβ pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TβRI (ALK5). Curr Opin Drug Discov Devel 2004; 7: 437–45.
Cited by
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
Self-citationTargeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Taube, J. H., Herschkowitz, J. I., Komurov, K., Zhou, A. Y., Gupta, S., Yang, J., Hartwell, K., Onder, T. T., Gupta, P. B., Evans, K. W., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004900107 · Cited by 1,041
The polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940
Metadata
- Authors
- Suzuki, E., Kim, S., Cheung, H.-K., Corbley, M. J., Zhang, X., Sun, L., Shan, F., Singh, J., Lee, W.-C., Albelda, S. M., & Ling, L. E.
- Affiliations
- University of Pennsylvania (US)
- Biogen (United States) (US)
- 1Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania and
- Venue
- Cancer Research
- Published
- 2007-03-01
- Volume
- 67
- Issue
- 5
- Pages
- 2351-2359
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2122411707
- Cited by
- 113
- References
- 61
- Citations by year
- 2025: 4 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 3 · 2017: 3 · 2016: 3 · 2015: 5 · 2014: 10 · 2013: 8 · 2012: 17
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P01CA066726)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- malignant mesothelioma, TGF-beta type I receptor, TGF-beta signaling, Smad2/3 phosphorylation, tumor recurrence after resection, CD8+ T cells, antitumor immunity, oral drug delivery, small-molecule kinase inhibitors
- MeSH terms
- Receptor, Transforming Growth Factor-beta Type I, Animals, Drug Evaluation, Preclinical, Female, Humans, Immunity, Cellular, Mesothelioma, Mice, Inbred BALB C, Neoplasm Recurrence, Local, Neoplasm Transplantation, Tumor Cells, Cultured, Mice, SCID, Protein Serine-Threonine Kinases, Receptors, Transforming Growth Factor beta, Disease-Free Survival, Activin Receptors, Type I, Protein Kinase Inhibitors, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Novel Small-Molecule Inhibitor of Transforming Growth Factor β Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-2389
- The paper
- Suzuki, E., Kim, S., Cheung, H.-K., Corbley, M. J., Zhang, X., Sun, L., Shan, F., Singh, J., Lee, W.-C., Albelda, S. M., & Ling, L. E. (2007). A Novel Small-Molecule Inhibitor of Transforming Growth Factor β Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-2389
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.